A Study of LY3200882 in Participants With Solid Tumors

NCT02937272 · tracked via the Priya Life Science USA tracker

Sponsor

Eli Lilly and Company

Phase

Phase 1

Started

2016-11-21

Last updated

2026-04-03

Condition(s) studied

Solid Tumor

Investigational drug(s) / intervention(s)

LY3200882LY3300054Gemcitabinenab-PaclitaxelCisplatinIntensity Modulated Radiotherapy

LY3200882: Administered orally

LY3300054: Administered intravenously

Gemcitabine: Administered intravenously

nab-Paclitaxel: Administered intravenously

Cisplatin: Administered intravenously

Study summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3200882 in participants with solid tumors.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * The participant must have histological or cytological evidence of cancer. * Have adequate organ function. * Have Eastern Cooperative Oncology Group (ECOG) scale performance status of 0 or 1. * Are able to swallow capsules and tablets. Exclusion Criteria: * Have moderate or severe cardiovascular disease. * Have a serious concomitant systemic disorder. * Have acute leukemia.

Primary outcome measure(s)

Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — Cycle 1 (28 days)
Part B: Overall Response Rate (ORR): Percentage of Participants with Complete Response (CR) or Partial Response (PR) — Baseline through Disease Progression or Death (estimated at up to 12 months)

Trial sites (18)

Facility	City	Region
University of Louisville	Louisville	Kentucky
Weill Cornell Medical College	New York	New York
University of Texas MD Anderson Cancer Center	Houston	Texas
Calvary Mater Newcastle	Newcastle	New South Wales
St Vincent's Hospital Sydney	Sydney	New South Wales
Greenslopes Private Hospital	Greenslopes	Queensland
Princess Margaret Hospital (Ontario)	Lai Chi Kok	Kowloon
Hopital Saint-Louis	Paris	Cedex 10
CHRU de Lille	Lille	France
Gustave Roussy	Villejuif	France
Universitätsklinikum Würzburg A. ö. R.	Würzburg	Bavaria
Charité Campus Virchow-Klinikum	Berlin	Germany
Istituto Clinico Humanitas	Rozzano	Milano
Ospedale Policlinico Giambattista Rossi, Borgo Roma	Verona	Italy
National Cancer Center Hospital	Chuo-Ku	Tokyo
Hospital Universitari Vall d'Hebron	Barcelona	Spain
Hospital Universitario 12 de Octubre	Madrid	Spain
Hospital Clínico Universitario de Valencia	Valencia	Spain

More Eli Lilly and Company trials in the USA

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity Active, not recruiting

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors Recruiting

A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein) Starting soon

A Real-World Comparative Study of Donanemab (LY3002813) Plus Usual Care Versus Usual Care Alone in US Participants With Early Symptomatic Alzheimer's Disease Recruiting

A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight Starting soon

Other trials for the same condition

Dabrafenib and/or Trametinib Rollover Study Recruiting

A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors Active, not recruiting

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion Active, not recruiting

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Recruiting

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02937272 on ClinicalTrials.gov ↗ ← All trials in the USA